tetano
Editor, Senior Moderator
J Immunol
. 2021 Oct 4;ji2100606.
doi: 10.4049/jimmunol.2100606. Online ahead of print.
SARS-CoV-2-Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals
Yanling Liu[SUP] 1 [/SUP], Patrick Budylowski[SUP] 2 [/SUP], Shilan Dong[SUP] 1 [/SUP], Zhijie Li[SUP] 3 [/SUP], Sofiya Goroshko[SUP] 1 [/SUP], Leslie Y T Leung[SUP] 1 [/SUP], Eyal Grunebaum[SUP] 4 [/SUP], Paolo Campisi[SUP] 5 [/SUP], Evan J Propst[SUP] 5 [/SUP], Nikolas E Wolter[SUP] 5 [/SUP], James M Rini[SUP] 3 6 [/SUP], Amin Zia[SUP] 7 [/SUP], Mario Ostrowski[SUP] 1 2 [/SUP], Götz R A Ehrhardt[SUP] 8 [/SUP]
Affiliations
Abstract
SARS-CoV-2 is a respiratory pathogen that can cause severe disease in at-risk populations but results in asymptomatic infections or a mild course of disease in the majority of cases. We report the identification of SARS-CoV-2-reactive B cells in human tonsillar tissue obtained from children who were negative for coronavirus disease 2019 prior to the pandemic and the generation of mAbs recognizing the SARS-CoV-2 Spike protein from these B cells. These Abs showed reduced binding to Spike proteins of SARS-CoV-2 variants and did not recognize Spike proteins of endemic coronaviruses, but subsets reacted with commensal microbiota and exhibited SARS-CoV-2-neutralizing potential. Our study demonstrates pre-existing SARS-CoV-2-reactive Abs in various B cell populations in the upper respiratory tract lymphoid tissue that may lead to the rapid engagement of the pathogen and contribute to prevent manifestations of symptomatic or severe disease.
. 2021 Oct 4;ji2100606.
doi: 10.4049/jimmunol.2100606. Online ahead of print.
SARS-CoV-2-Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals
Yanling Liu[SUP] 1 [/SUP], Patrick Budylowski[SUP] 2 [/SUP], Shilan Dong[SUP] 1 [/SUP], Zhijie Li[SUP] 3 [/SUP], Sofiya Goroshko[SUP] 1 [/SUP], Leslie Y T Leung[SUP] 1 [/SUP], Eyal Grunebaum[SUP] 4 [/SUP], Paolo Campisi[SUP] 5 [/SUP], Evan J Propst[SUP] 5 [/SUP], Nikolas E Wolter[SUP] 5 [/SUP], James M Rini[SUP] 3 6 [/SUP], Amin Zia[SUP] 7 [/SUP], Mario Ostrowski[SUP] 1 2 [/SUP], Götz R A Ehrhardt[SUP] 8 [/SUP]
Affiliations
- PMID: 34607939
- DOI: 10.4049/jimmunol.2100606
Abstract
SARS-CoV-2 is a respiratory pathogen that can cause severe disease in at-risk populations but results in asymptomatic infections or a mild course of disease in the majority of cases. We report the identification of SARS-CoV-2-reactive B cells in human tonsillar tissue obtained from children who were negative for coronavirus disease 2019 prior to the pandemic and the generation of mAbs recognizing the SARS-CoV-2 Spike protein from these B cells. These Abs showed reduced binding to Spike proteins of SARS-CoV-2 variants and did not recognize Spike proteins of endemic coronaviruses, but subsets reacted with commensal microbiota and exhibited SARS-CoV-2-neutralizing potential. Our study demonstrates pre-existing SARS-CoV-2-reactive Abs in various B cell populations in the upper respiratory tract lymphoid tissue that may lead to the rapid engagement of the pathogen and contribute to prevent manifestations of symptomatic or severe disease.